DataSheet_1_Cervicovaginal Immune Activation in Zambian Women With Female Genital Schistosomiasis.docx
HIV-1 infection disproportionately affects women in sub-Saharan Africa, where areas of high HIV-1 prevalence and Schistosoma haematobium endemicity largely overlap. Female genital schistosomiasis (FGS), an inflammatory disease caused by S. haematobium egg deposition in the genital tract, has been associated with prevalent HIV-1 infection. Elevated levels of the chemokines MIP-1α (CCL-3), MIP-1β (CCL-4), IP-10 (CXCL-10), and IL-8 (CXCL-8) in cervicovaginal lavage (CVL) have been associated with HIV-1 acquisition. We hypothesize that levels of cervicovaginal cytokines may be raised in FGS and could provide a causal mechanism for the association between FGS and HIV-1. In the cross-sectional BILHIV study, specimens were collected from 603 female participants who were aged 18–31 years, sexually active, not pregnant and participated in the HPTN 071 (PopART) HIV-1 prevention trial in Zambia. Participants self-collected urine, and vaginal and cervical swabs, while CVLs were clinically obtained. Microscopy and Schistosoma circulating anodic antigen (CAA) were performed on urine. Genital samples were examined for parasite-specific DNA by PCR. Women with FGS (n=28), defined as a positive Schistosoma PCR from any genital sample were frequency age-matched with 159 FGS negative (defined as negative Schistosoma PCR, urine CAA, urine microscopy, and colposcopy imaging) women. Participants with probable FGS (n=25) (defined as the presence of either urine CAA or microscopy in combination with one of four clinical findings suggestive of FGS on colposcope-obtained photographs) were also included, for a total sample size of 212. The concentrations of 17 soluble cytokines and chemokines were quantified by a multiplex bead-based immunoassay. There was no difference in the concentrations of cytokines or chemokines between participants with and without FGS. An exploratory analysis of those women with a higher FGS burden, defined by ≥2 genital specimens with detectable Schistosoma DNA (n=15) showed, after adjusting for potential confounders, a higher Th2 (IL-4, IL-5, and IL-13) and pro-inflammatory (IL-15) expression pattern in comparison to FGS negative women, with differences unlikely to be due to chance (p=0.037 for IL-4 and p<0.001 for IL-5 after adjusting for multiple testing). FGS may alter the female genital tract immune environment, but larger studies in areas of varying endemicity are needed to evaluate the association with HIV-1 vulnerability.
History
References
- https://doi.org//10.1016/j.actatropica.2020.105524
- https://doi.org//10.1097/01.aids.0000210614.45212.0a
- https://doi.org//10.1371/journal.pntd.0001170
- https://doi.org//10.4269/ajtmh.2011.11-0135
- https://doi.org//10.1371/journal.pone.0098593
- https://doi.org//10.1016/s0001-706x(96)00026-5
- https://doi.org//10.1093/cid/civ298
- https://doi.org//10.1097/COH.0000000000000232
- https://doi.org//10.1073/pnas.86.7.2336
- https://doi.org//10.1136/sextrans-2014-051601
- https://doi.org//10.1038/mi.2015.51
- https://doi.org//10.1128/CVI.00762-14
- https://doi.org//10.1093/infdis/jis298
- https://doi.org//10.1016/j.immuni.2016.12.013
- https://doi.org//10.1371/journal.pone.0043951
- https://doi.org//10.1371/journal.pone.0143109
- https://doi.org//10.1097/00002030-200108170-00011
- https://doi.org//10.1128/IAI.01822-05
- https://doi.org//10.1093/infdis/jiy742
- https://doi.org//10.1086/429334
- https://doi.org//10.1056/NEJMoa1814556
- https://doi.org//10.1371/journal.pntd.0008337
- https://doi.org//10.1017/S0031182014000626
- https://doi.org//10.1016/s0001-706x(00)00115-7
- https://doi.org//10.4269/ajtmh.19-0819
- https://doi.org//10.1179/136485908X337490
- https://doi.org//10.4269/ajtmh.13-0406
- https://doi.org//10.1186/s12879-015-0825-z
- https://doi.org//10.1371/journal.pone.0089212
- https://doi.org//10.1038/nri2992
- https://doi.org//10.1186/1471-2334-7-139
- https://doi.org//10.1371/journal.ppat.1002605
- https://doi.org//10.1086/344352
- https://doi.org//10.4049/jimmunol.164.5.2585
- https://doi.org//10.1038/356604a0
- https://doi.org//10.1086/323802
- https://doi.org//10.1111/j.0105-2896.2004.00195.x
- https://doi.org//10.1155/2018/9754060
- https://doi.org//10.1038/nri843
- https://doi.org//10.4049/jimmunol.1401706
- https://doi.org//10.1038/s41467-019-09900-9
- https://doi.org//10.1128/IAI.00291-18
- https://doi.org//10.4269/ajtmh.2005.72.311
- https://doi.org//10.4103/1742-6413.180784
- https://doi.org//10.1097/QAI.0b013e3182961cfc
- https://doi.org//10.1093/infdis/jiw096
- https://doi.org//10.1371/journal.pone.0131906
- https://doi.org//10.1371/journal.pntd.0002104
- https://doi.org//10.1016/j.trstmh.2005.09.010
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity